KP136  (Synonyms: AL136)

KP136 (AL136) is an orally effective antiallergic agent. The IC₅₀ is 76.1 μg/mL for histamine release and 63 ug/mL for degranulation^[1].

Histamine release^[1]

KP136 (0.01 μg/mL) inhibits this histamine release and degranulation in a dose-dependent manner, confirming that it is an inhibitor of mast cell activation. The IC₅₀ is 76.1 μg/mL for histamine release and 63 ug/mL for degranulation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

C4C at 0.2 mg/kg produces an equipotent effect to 1 mg/kg KP136 (KP-136) or 5 mg/kg DSCG. However, C4C is less effective by the oral route because it only produces a maximum inhibition of about 35% even at the high dose of 100 mg/kg, whereas KP136 shows an overt inhibitory effect of about 66% at the oral dose of 2 mg/kg. On the other hand, KP136 (1 mg/kg, i.v.) also remarkably inhibits 5-h homologous PCA, having an activity similar to that of C4C^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

314.34

C₁₆H₁₈N₄O₃

76239-32-2

O=C1C(C2=NNN=N2)=CC3=CC=CC(OCCCCCC)=C3O1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kuriyama K, et al. Antiallergic effects of 4-[2-oxo-3-(1H-tetrazol-5-yl)-2H-chromen-8-yloxy]-bu tyric acid. Jpn J Pharmacol. 1989 Jun;50(2):111-8.  [Content Brief]